Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Helsinki University |
---|---|
Information provided by: | Helsinki University |
ClinicalTrials.gov Identifier: | NCT00548002 |
To study whether fluoroquinolone (trovafloxacin or levofloxacin), added to standard treatment, could reduce the high mortality and complication rates in Staphylococcus aureus bacteremia.
Condition | Intervention | Phase |
---|---|---|
Staphylococcus Aureus Bacteremia Endocarditis Sepsis |
Drug: trovafloxacin and levofloxacin |
Phase IV |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Whole blood
Enrollment: | 430 |
Study Start Date: | January 1999 |
Study Completion Date: | August 2002 |
Groups/Cohorts | Assigned Interventions |
---|---|
1 and 2
Patients were randomly assigned to receive either 1) standard treatment or 2) standard treatment combined with a fluoroquinolone (trovafloxacin or levofloxacin).
|
Drug: trovafloxacin and levofloxacin
Trovafloxacin: <60 kg 200 mg iv/orally once daily and >60 kg 300 mg iv/orally once daily Levofloxacin: < 60 kg 500 mg iv/orally once daily and >60 kg 500 mg iv/orally bid
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Adult patients with at least 1 blood culture positive for Staphylococcus aureus were included within 1 to 7 days of blood culture sampling.
Inclusion Criteria:
Adult patients with at least 1 blood culture positive for Staphylococcus aureus were included within 1 to 7 days of blood culture sampling.
Exclusion Criteria:
Finland, HUS | |
Division of Infectious Diseases, Department of Medicine, Helsinki University Central Hospital | |
Helsinki, HUS, Finland, 00029 |
Principal Investigator: | Eeva Ruotsalainen, MD | Division of Infectious Diseases, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland |
Study ID Numbers: | 210275 |
Study First Received: | October 22, 2007 |
Last Updated: | October 22, 2007 |
ClinicalTrials.gov Identifier: | NCT00548002 |
Health Authority: | Finland: Ethics Committee; Finland: National Agency for Medicines |
Staphylococcus aureus bacteremia endocarditis sepsis |
fluoroquinolone rifampin levofloxacin trovafloxacin |
Bacterial Infections Systemic Inflammatory Response Syndrome Heart Diseases Fluoroquinolones Ofloxacin Bacteremia Endocarditis |
Inflammation Rifampin Staphylococcal Infections Sepsis Gram-Positive Bacterial Infections Trovafloxacin Alatrofloxacin |
Anti-Infective Agents Anti-Bacterial Agents Pathologic Processes Molecular Mechanisms of Pharmacological Action Therapeutic Uses Anti-Infective Agents, Urinary |
Enzyme Inhibitors Cardiovascular Diseases Renal Agents Infection Nucleic Acid Synthesis Inhibitors Pharmacologic Actions |